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Fatigue is a common yet poorly understood and underresearched nonmotor symptom in Parkinson’s disease. Although fatigue is
recognized to signiﬁcantly aﬀect health-related quality of life, it remains underrecognised and empirically treated. In this paper,
the prevalence of fatigue as measured by a validated visual analogue scale and the Parkinson’s disease nonmotor symptoms scale
(PDNMSS) was correlated with other motor and nonmotor comorbidities. In a cohort of patients from a range of disease stages,
occurrence of fatigue correlated closely with more advanced Parkinson’s disease, as well as with depression, anxiety, and sleep
disorders, hinting at a common underlying basis.
1.Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder which is known to be associated with nonmotor
symptoms (NMS) including dribbling of saliva, consti-
pation, depression, sleep disorders, apathy, hallucinations,
and dementia [1]. NMS of PD contributes signiﬁcantly to
health-related quality of life (HrQoL) and some NMS such
as constipation, hyposmia, rapid eye movement behavior
disorder (RBD), fatigue, and depression may be markers of
a preclinical stage of PD [2, 3]. In spite of its clinical and
patient-related importance, NMS remain undeclared and
often undertreated in primary or secondary care [4].
Fatigue is now recognized as a key NMS in PD. It may
be present at diagnosis and can complicate late disease and
become an overwhelming problem for patients and relatives
[5–7]. Indeed, fatigue impacts most dimensions of HrQoL
even as a factor independent of depression and disability [8–
10]. The largest holistic study of NMS in PD, the PRIAMO
study, reported fatigue to be prevalent in 58.1% of a popu-
lation sample of 1072 patients ranging from 37.7% in early
(Hoehn and Yahr (HY) stage 1) PD to 81.6% in advanced
(HY stage 5) [11]. Other studies have suggested a prevalence
between 33% to 58%, although the method of diagnosis and
deﬁnition of “fatigue” is heterogeneous [7, 12–16]. However,
there is a poor correlation between the severity of mental2 Parkinson’s Disease
and physical fatigue suggesting independent aetiologies [17].
Since there is as yet no biomarker of fatigue, patient-
reported questionnaires remain the mainstay of measuring
and diagnosing fatigue. Speciﬁc scales for clinical assessment
of fatigue have now been validated for PD and can be
used in the clinic while “holistic” nonmotor scales can be
used to explore the relationship of other key NMS of PD
such as depression, apathy, excessive daytime sleepiness, and
fatigue. The Parkinson’s nonmotor group (PDNMG) led
pivotal studies validating the ﬁrst nonmotor questionnaire
(NMSQuest) and subsequently, the nonmotor scale (NMSS)
for PD [18–20]. Fatigue is a key component of domain 2
of the NMSS. It is scored based on the multiplication of
its severity and its frequency—a measure that was validated
based on the collection of data from an unselected cohort of
PD patients from a number of international centers.
Fatigue in PD occurs independent of motor severity.
There is a paucity of research exploring the treatment of
fatigue in PD. There is conﬂicting evidence regarding the
eﬃcacy of levodopa in treating fatigue [21, 22] while it
may be alleviated using methylphenidate [23]. Independent
of PD, large cohort [24–26]s t u d i e sh a v ea s s o c i a t e df a t i g u e
with a more sedentary lifestyle. Only one study, which
evaluated patients with PD, found that lower levels of
physical activity, poorer physical function, and less frequent
strenuous exercise were associated with increased fatigue
(see the work of Garber and Friedman [27]). A study on
rats which had 6-OHDA lesioning [28]h a ss u g g e s t e da
link between increased exercise and reduced loss of striatal
dopamine concentrations, with another study showing that
later intervention with exercise did not improve deﬁcits
[29]. However, no animal studies to date have demonstrated
an improvement of fatigue with exercise, and there is no
evidence yet to recommend the eﬃcacy of exercise therapy
on fatigue in PD in humans.
In this study, we have analysed the prevalence of fatigue
from the composite data set used to validate the nonmotor
symptom scale. We attempted to explore if other measures
used in the study contributed or could be marked as
“predictors” of fatigue in this population. We also aimed to
discern whether disease severity or pharmacological treat-
ment of PD aﬀected the prevalence of fatigue. An improved
understanding of this poorly researched area of nonmotor
symptoms in PD could then guide a holistic treatment
strategy.
2. Methods
2.1. Design. This data is obtained from the database related
to the validation study of the NMSS [18] which was
an international, cross-sectional, open, multicentre, one
point-in-time evaluation with retest study. Details of the
administration of the scales have been published previously.
2.2. Patients. Consecutive patients with PD (patients with
Parkinsonism were excluded), of all age groups and disease
severity, satisfying the UK PD Brain Bank criteria for
diagnosis of idiopathic PD were included after attending
relevant outpatient clinics [30]. Patients with a diagnosis of
parkinsonism due to alternative causes were excluded.
Patients were recruited from specialist movement disor-
der clinics at the National Parkinson Foundation centre of
excellence at King’s College and Lewisham Hospitals (UK)
and also local Care of the Elderly clinics. This ensured that
we recruited a range of patients from the composite group.
Cases with disease severity spanning Hoehn and Yahr (HY)
stages 1 to 5 were studied, and we also attempted to include a
proportion of untreated cases. Datasets were included where
fatigue data was available and computable.
Only patients able to provide informed consent were
selected for the study and demented patients were excluded.
The latter would mean that the clinician would exclude
patients with signiﬁcant cognitive impairment that
(i) aﬀected their ability to provide informed consent,
(ii) aﬀected their ability to complete self-reported items.
The data presented relates to 135 patients included
largely from the King’s/Lewisham, German and Italian sites.
3.EthicalApproval
Central ethical approval for the full study was initially
obtained via the research ethics committee at University
HospitalLewishamandsubsequentlyallcentresobtainedsite
speciﬁc ethical approval.
4. Procedure
The scales (listed below) and the nonmotor symptom
questionnaire used in the study were applied following a
standardized protocol, always in the same order, and there
was no reported patient fatigue while completing the scales
[3, 18]. Patient and carers took approximately 25 minutes
to complete the questionnaire while the investigator-led
instruments took 40 minutes to complete.
5. Assessments
The researcher then completed the following battery of
standard assessment measures:
(i) standard demography form,
(ii) uniﬁed Parkinson’s disease rating scale (UPDRS)
[31],
(iii) cumulative illness rating scale-geriatrics [32]( C I R S -
G to measure physical comorbidity),
(iv) Hoehn and Yarh scale [33],
(v) frontal assessment battery [34]( F A B ) ,
(vi) nonmotor symptom scale [18].
Sections 3 and 4 of the UPDRS were applied. These
domains evaluate motor examination and complications of
therapy,respectively.Thefrontalassessmentbatteryisashort
scale exploring assessing cognitive and behavioural function,
as a measure of executive capacity in PD.Parkinson’s Disease 3
In addition, the patient (assisted by the research nurse if
necessary) completed the following self-assessments:
(i) PDQ-8 [35] (a speciﬁc instrument for assessment of
health-related quality of life in PD),
(ii) a fatigue-visual analogue scale (VAS-F) [36],
(iii) hospital anxiety and depression Scale (HADS) [37]
(a self-administered instrument developed for the
detection of mood disorders in nonpsychiatric out-
patients attending hospital consulting rooms).
The total time required for a single assessment was ap-
proximately 65 minutes per patient.
5.1. Fatigue. For this study the VAS was used as a measure
of convergent validity with the fatigue section of the
NMSS. Fatigue was assessed using the fatigue VAS validated
speciﬁcally for PD. Patients were asked about the severity of
perceived fatigue by means of visual analogue scale (VAS)
where 0 represented the worst imaginable fatigue state to 100
representing no fatigue at all [37].
5.2. The NMS Scale. The NMS scale is composed of 30
items grouped in 9 domains: cardiovascular, sleep/fatigue,
mood/apathy, perceptual problems, attention/memory, gas-
trointestinal, urinary, sexual function, and miscellaneous.
Each item is scored for frequency (ranging from 1 (rarely) to
4 (very frequent)) and intensity (ranging from 0 (none) to 3
(severe)). The product of these scores gives the item severity
score (0 to 12). Domains and NMSS total scores are obtained
by the sum of items scores. The scale has been extensively
validated in two large international studies exceeding 700
patients [3, 18].
5.3. Inclusion/Exclusion Criteria. All patients with estab-
lished diagnosis of PD satisfying the UK Brain bank criteria
were included while all cases of Parkinsonism due to other
causes were excluded [13]. Additionally, after data had
been collected, patients whose clinical assessments indicated
dementia, severe depression (HADS > 13), or major sleep
disturbances were excluded as these factors may confound
assessment of fatigue.
5.4. Statistics. Descriptive statistics were used for the study
variables as needed. For comparisons, the Pearson’s chi-
squared, Mann-Whitney test (to test between two groups),
and Kruskal-Wallis test (to compare more than two groups)
were applied, as the variables did not meet the assumptions
for use of parametric statistics. Looking for a balance
between error types I and II adjustment for multiple
comparisons, the Benjamini-Hochberg method was applied.
Association of nonlinear relationships was analyzed by
Spearmanrankcorrelationcoeﬃcient(rs)withanalphalevel
set at 0.0001 but with a Bonferroni downward adjustment
for multiple comparisons. The statistical software SPSS 19.0
(IBM, USA) was used for data analysis.
6. Results
A total of 135 patients met eligibility criteria with complete
datasets. Demographic details and summary of measures are
shown in Tables 1–5. Patients had a mean age of 69.7 ± 10.52
years and an age range of 35 to 88yrs (24.4% TD, 28.9% AD,
46.6%mixed).However,asthiswasaclinic-basedstudy,only
2% were HY stage 5 while the majority were between HY
stages 2-3 (Table 4). The breakdown of NMSS scores in each
domain is shown in Table 6.
Data from the application of the fatigue-speciﬁc visual
analogue scale showed no signiﬁcant diﬀerences between
males (1) and females (2) using the Mann-Whitney test
(male 62 ± 20.4 versus female 63.1 ± 19.2). Analysis of
fatigue scores (grouped as mild, moderate, or severe) using
HY staging of disease progression (HY 1–2.5 = 7( m i l d
fatigue); HY 3 = 8 (moderate fatigue); HY 4-5 = 9( s e v e r e
fatigue)) showed a signiﬁcant correlation (P = 0.004) using
the Kruskal-Wallis test as seen in Table 3. No signiﬁcant
diﬀerences were observed in fatigue scores between the
diﬀerent drug treated and drug na¨ ıve patients using the
Mann-Whitney test. Correlation measures using Spearman
rank correlation coeﬃcient were used between the various
variables and fatigue scores and are listed in Table 7.
Correlation measures using the Spearman rank correla-
tion coeﬃcient associating measured variables from UPDRS,
CIRS, HADS, FAB, PDQ-8, Hoehn & Yahr, NMSQuest, and
NMSS instruments are also shown in Table 7.I n c r e a s e d
fatigue was independently correlated strongly (r<−0.30,
P<0.0001) with HADS anxiety and depression domains,
FAB score, total NMSQuest score, total NMSS score, HRQo
measured by PDQ-8, and NMS sleep and mood domains.
7. Discussion
Fatigue was noted by James Parkinson (1817) in his original
description of the disorder, but it is only in 1993 that studies
began describing its prevalence, progression, and impact and
characterising fatigue [7].
Studies since then have suggested that sleep disorders,
medications, and depression may be possible secondary
causes of fatigue in individuals with PD [6]. The prevalence
ofautonomicimpairment, nocturnalsleepdisturbances,and
depression have been found to exacerbate the subjective
perception of fatigue. However, fatigue occurs in patients
with PD independent of sleep dysfunction and in nonde-
pressed patients, suggesting that these factors may not be
the only contributors to the high prevalence of fatigue in
PD patients. Indeed, population-based studies in PD report
that sleep disorders and in particular excessive daytime
somnolence (EDS) do not account for fatigue in the majority
of PD subjects. This relationship is, however, clouded by
evidence showing that certain medications used to treat PD
are associated with EDS [6].
The PRIAMO study showed that fatigue is present in
patients presenting at Hoehn and Yahr stage 1 of the disease
while the percentage of patients with fatigue rises as the
disease progresses to stage 5 [11]. It is likely that in the
majority of PD patients, fatigue is intrinsic to the disease.4 Parkinson’s Disease
Table 1: Distribution of disease severity as measured by Hoehn and
Yahr stage (H & Y stage).
H&Ys t a g e P a t i e n t s( n) Percent (%)
1 16 11.85
1.5 17 12.59
2 22 16.30
2.5 20 14.81
3 42 31.11
4 15 11.11
5 3 2.22
Table 2: Distribution of patients after H & Y stage grouped by
severity.
H & Y categories Patients (n) Percent (%)
Mild 75 55.56
Moderate 42 31.11
Severe 18 13.33
Subdivisions: H & Y 1–2.5 = (mild); 3 = (moderate); 4 + 5 = (severe).
Table 3: Analysis of fatigue scores using Hoehn and Yahr staging
of disease progression showed a signiﬁcant correlation (P = 0.004)
using the Kruskal-Wallis test.
H & Y categories Mean fatigue score Std. Dev.
Mild 67.52 18.33
Moderate 56.83 17.16
Severe 54.94 26.44
Table 4: The distribution of antiparkinsonian therapy used in the
patients studied.
Therapies Patients (n) Percent (%)
Drug na¨ ıve 12 8.89
Levodopa monotherapy 50 37.04
DA monotherapy 11 8.15
Levodopa + DA 61 45.19
Others 1 0.74
DA: dopamine agonists.
Our current study was aimed at exploring these various
issues, in particular by using PD-speciﬁc fatigue measures
which were used as secondary variable measure in the orig-
inal validation study of NMSS, and employing correlation
measures with seemingly confounding variables. The patient
base was “real life” and representative of a PD population.
We found no diﬀerence in fatigue scores between sub-
types of PD. Akinesia dominant cases had similar levels of
fatigue compared to tremor dominant types, and fatigue lev-
els were similar between male and female patients. However,
using Kruskall-Wallis comparative measures, fatigue levels
worsened signiﬁcantly with worsening disease severity as
measured by HY stage and graded as mild, moderate, and
Table 5: A uniﬁed table showing demographic values and assess-
ment scores in this study.
Variable Patients (n) Mean SD Minimum Maximum
Age 135 69.74 10.52 25 88
Duration 135 5.78 5.19 0 32
Agedx 135 63.88 11.34 29 65
UPDRS 3 130 16.13 8.01 2 44
UPDRS 4 132 2.92 3.03 0 13
Dysk & Flct 132 2.32 2.74 0 12
CIRS Total 135 4.74 2.84 0 15
VAS-F 135 62.52 19.90 10 100
HADS Anx 135 10.73 4.79 0 21
HADS Dep 135 10.19 4.62 1 21
FAB Total 134 14.79 2.83 3 18
PDQ-8 134 28.19 17.82 0 78.13
SD: standard deviation, duration = duration of disease, agedx: age at
diagnosis. Dysk & Flct: dyskinesia and ﬂuctuation, UPDRS 3 and 4: uniﬁed
Parkinson’s disease rating scale domains 3 & 4, CIRS: cumulative illness
rating scale, VAS-F: fatigue-speciﬁc visual analogue scale, HADS Anx &
Dep: hospital anxiety and depression rating scale anxiety and depression
domains, FAB: frontal assessment battery.
Table 6: Table showing nonmotor scale (NMSS) data distribution
including subitem scores.
Variable Patients (n) Mean Std. Dev. Min Max
GI 135 4.38 5.14 0 23
Urinary 135 6.44 7.01 0 36
CV 133 2.60 4.04 0 21
Sexual function 135 3.08 5.66 0 24
Sleep/fatigue 135 11.11 9.03 0 48
Perception 135 1.81 4.43 0 36
Mood 135 10.56 14.34 0 72
Attention/memory 135 5.97 8.03 0 36
Misc. 135 6.66 7.38 0 36
NMSS total 133 52.96 41.52 0 243
GI: gastrointestinal, CV: cardiovascular, Misc.: miscellaneous, NMSS total:
total score on NMSS.
severe (Table 2). This observation is in line with the recently
reported PRIAMO study where fatigue levels were reported
incrementally as HY stages increased [11]. However, it is to
be noted that a substantial proportion of mild PD cases,
including drug na¨ ıve PD patients, experienced some level of
fatigue.
The level of fatigue between drug na¨ ıve cases and
those treated with either mono or combination therapy
of antiparkinsonian agents were similar and provides an
indirect support for the observation that fatigue in PD
appears to be unaﬀected by conventional PD therapy.
However, we observed a trend (although nonsigniﬁcant) of
better fatigue scores in those treated by combined levodopa
and dopamine agonists (fatigue score of 71.3 ± 19.1 in
untreated PD versus fatigue score of 60.6 ± 20.6 in combined
therapy). At least one study has suggested that pergolide, anParkinson’s Disease 5
Table 7: Correlation measures using Spearman rank correlation
coeﬃcient measures between the various variables and fatigue
scores.
Variable rP
Age — N.S.
UPDRS domain 3 −0.2380 =0.0064
UPDRS domain 4 −0.1968 0.0237
CIRS total — N.S.
CIRS domain 1 — N.S.
HADSanxiety domain −0.3948 <0.0001
HADS depression domain −0.4171 <0.0001
Frontal assessmentbattery 0.3374 =0.0001
NMSQuest total −0.3122 =0.0003
NMSQuest sleep domain −0.2823 =0.0009
Other NMSQuest domains — N.S.
Hoehn & Yahr staging −0.2882 =0.0007
PDQ-8 −0.367 <0.0001
NMSS total −0.3924 <0.0001
NMSS cardiovascular domain −0.2985 =0.0004
NMSS sexual function domain −0.2576 =0.003
NMSS sleep domain −0.3908 <0.0001
NMSS mooddomain −0.3766 <0.0001
NMSS attention/memory domain −0.2574 =0.003
NMSS misc. domain −0.2666 0.002
Other NMSS domains — N.S.
The key correlations (P<0.0001) are highlighted (N.S.: not signiﬁcant,
UPDRS: uniﬁed Parkinson’s disease rating scale, CIRS: cognitive impair-
ment rating scale, HADS: hospital anxiety and depression scale, NMSQuest:
nonmotor symptom questionnaire, NMSS: nonmotor symptom scale).
ergot dopamine agonist may improve fatigue in PD although
controlled studies are lacking [38].
Finally, in an attempt to unravel the positive correlations
of fatigue and other measures in PD, a detailed correlation
analysiswasundertaken(Table7).Thekeyﬁndingswerethat
anxiety and depression as measured by the HADS anxiety
and depression subscales, and the mood domain of NMSS
showed a robust association with fatigue scores on VAS.
Sleep dysfunction was also associated highly signiﬁcantly
with fatigue while HY score also registered a signiﬁcant asso-
ciation. All together this translated to a robust association
with health-related quality of life as measured by PDQ-8.
The association of fatigue with sleep dysfunction and
anxiety and depression appears conﬁrmatory with other
observations as quoted previously while the lack of associ-
ation with age, sex, and pattern of PD is also in line with
established views on fatigue [6]. Statistically the dominant
predictive factors of fatigue emerging from this study are
depression, anxiety, and sleep dysfunction. This was our a
priori hypothesis and may support a view held by Shulman
et al. who suggested that nonmotor symptoms of PD such
as fatigue, depression, and pain could share the same
pathogenic origin [39].
Indeed, a recent study suggests that reduced serotonin
(and perhaps dopamine) in certain areas of the brain
may provide the pathophysiological basis of fatigue in
PD [40]. Pavese et al. [40] used 11C-DASB imaging to
demonstrate reduced serotonin transporter binding in the
caudate, putamen, ventral striatum, and thalamus in PD
patients with fatigue. Although there was no diﬀerence
between nigrostriatal dopamine levels as measured by 15F-
dopa values, reduced uptake in the insular cortex of PD
patients with fatigue points to a link between fatigue and loss
of extrastriatal dopaminergic function. Methylphenidate, a
dopaminetransporterblocker,hasbeenshowntobeeﬀective
in improving fatigue in PD patients [23]. While SSRIs have
been used to treat chronic fatigue, and anecdotally to address
fatigue in PD, the 11C-DASB ﬁndings suggest that treatment
strategy should aim to restore serotonin levels rather than
inhibit its transport (via the serotonin transporter, SERT).
Although it is clinically diﬃcult to separate fatigue and
sleep given the diﬃculty a patient may have in distinguishing
the two, several studies have suggested that fatigue is an
independent nonmotor symptom unrelated to sleepiness
[7, 16]. Sleepiness in PD has been associated to damage to
central arousal systems by neuronal loss and Lewy bodies
in several areas including serotonergic neurons in the raphe
median nucleus.
Isolating depression from fatigue in PD can also be
challenging. Although it has been shown that fatigue occurs
more in the depressed patient than in the general population
[41, 42], this relationship is obscured by varying deﬁnitions
of “fatigue” in the literature. More so, symptoms of fatigue
and anergia contribute to the disability of depression.
However, there are reports demonstrating that PD patients
may experience depression and/or sleepiness without fatigue
[5]. Depression has long been associated with widespread
serotonergic loss [43, 44]. One small study has shown
that nortriptyline, a tricyclic antidepressant with moderate
antiserotoninreceptoreﬀects,improvedsymptomsoffatigue
[45].
Although it is unlikely that one neuronal hormone, be it
serotonin or dopamine, is responsible for fatigue, sleepiness,
anxiety,ordepressioninPD,thisstudyshowsacommonality
between these nonmotor symptoms, and is thus consistent
with the hypothesis proposed by Shulman et al. Less robust
association was observed for instance with cardiovascular
NMS such as orthostatic tolerance, sexual function, pain,
hyperhidrosis, attention, and memory functions (Table 7).
Further studies must be designed to disentangle the speciﬁc
relationship of these issues with fatigue, including the role of
sleep pattern in fatigued PD patients, and explore alternative
strategies to target the role of low central serotonin levels in
these patients.
In conclusion, this study suggests that fatigue is an
important independent nonmotor symptom of PD and is
associated with depression, anxiety, and sleep disorders.
Fatigue appears to be widespread irrespective of the motor
stage of PD and has a close correlation with quality of life in
people with Parkinson’s.
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